Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2007-10-26
2010-02-23
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S085200, C424S085400, C424S134100, C435S183000, C514S003100, C514S006900, C514S008100, C514S012200, C530S387100, C530S324000, C530S325000, C530S351000, C530S385000, C530S391100, C530S397000, C530S402000
Reexamination Certificate
active
07666400
ABSTRACT:
The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
REFERENCES:
patent: 4046722 (1977-09-01), Rowland
patent: 4699784 (1987-10-01), Shih et al.
patent: 4868109 (1989-09-01), Lansdorp et al.
patent: 5770198 (1998-06-01), Coller et al.
patent: 6261537 (2001-07-01), Klaveness et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6524854 (2003-02-01), Monia et al.
patent: 7060506 (2006-06-01), Craig
patent: 2003/0198956 (2003-10-01), Makowski et al.
patent: 2003/0232420 (2003-12-01), Braun et al.
patent: 2004/0018587 (2004-01-01), Makowski et al.
patent: 2004/0126361 (2004-07-01), Saifer et al.
patent: 2005/0003403 (2005-01-01), Rossi et al.
patent: 2006/0210475 (2006-09-01), Goldenberg et al.
patent: 2006/0228300 (2006-10-01), Chang et al.
patent: 2006/0228357 (2006-10-01), Chang et al.
patent: 2007/0086942 (2007-04-01), Chang et al.
patent: 2007/0140966 (2007-06-01), Chang et al.
patent: 2007/0264265 (2007-11-01), Goldenberg et al.
patent: 2009/0111143 (2009-04-01), Goldenberg et al.
patent: 0068248 (2000-11-01), None
patent: 2006/107617 (2006-10-01), None
patent: 2006/107786 (2006-10-01), None
patent: 2007/046893 (2007-04-01), None
patent: 2007/075270 (2007-07-01), None
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Seffernick et al, J Bacteriol 183 (8): 2405-10, Apr. 2001.
Foser et al, The Pharmacogenomics J 3: 312-319, 2003.
Chang et al, Clin Cancer Res 13(18 Suppl): 5586-5591, Sep. 15, 2007.
Alto et al., “Bioinformatic Design of A-kinase Anchoring Protein-in Silico: A Potent and Selective Peptide Antagonist of Type II Protein Kinase A Anchoring”, Proc. Natl. Acad. Sci, USA. 2003;100:4445.
Baillie et al., “Compartmentalisation of Phospodiesterases and Protein Kinase A: Opposites Attract”, FEBS Letters. 2005; 579:3264.
Basu et al., “Structure-Function Engineering of Interferon-B-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation”, Bioconjugate Chem. 2006;17:618
Carr et al., “Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs Through an Amphipathic Helix Binding Motif”, J. Biol. Chem. 1991;266:14188.
Colledge and Scott, “AKAPS: From Structure to Function”, Trends Cell Biol. 1999;6:216.
Dhalluin et al.,“Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-a2a and Its Individual Positional Isomers”, Bioconjugate Chem. 2005;16:504.
Doherty et al., “Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor”, Bioconjugate Chem. 2005;16:1291.
Goodson and Katre, “Site-Directed PEGlyation of Recombinant Interleukin-2 at its Glycosylation Site”, Nat. Biotechnology. 1990:8:343.
Grace et al., “Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-a Antiviral and Antiproliferative Activities Through the JAK/STAT Signaling Pathway”, J. Biol. Chem. 2005;280:6327.
Kinstler et al., “Characterization and Stability of N-terminally PEGylated rhG-CSF”, Pharm. Res. 1996;13:996.
Lee et al., “Solid-Phase PEGylation of Recombinant Interferon a-2a for Site-Specific Modification: Process Performance, Characterization, and in Vitro Bioactivity”, Bioconjug. Chem. 2007; 18:1728-34.
Newlon et al., “A Novel Mechanism of PKA Anchoring Revealed by Solution Structures of Anchoring Complexes”, EMBO J. 2001;20:1651.
Newlon et al., “The Molecular Basis for Protein Kinase A Anchoring Revealed by Solution NMR”, Nat. Struct. Biol. 1999;6:222.
Pepinsky et al., “Improved Pharmacokinetic Properties of a Polyethylene Glycol-Modified Form of Interferon-B-1a With Preserved in Vitro Bioactivity”, Pharmacol. Exp. Ther. 2001;297:1059.
Rosendahl et al., “A Long-Acting, Highly Potent Interferon a-2 Conjugate Created Using Site-Specific PEGylation”, Bioconjugate Chem. 2005;16:200.
Wong and Scott, “AKAP Signalling Complexes: Focal Points in Space and Time”, Nat. Rev. Mol. Cell Biol. 2004;5:959.
Rossi et al. “Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting” Proc. Natl. Acad. Sci. Epub Apr. 24, 2006, vol. 103, No. 18, pp. 6841-6846.
Rustandi et al. “The Ca2+-Dependent Interaction of S100B(ββ) with a Peptide Derived from p53”, Biochemistry 1998; 37: 1951-1960.
Sabaawy et al. “Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-α gene transfer” Int. J. Oncol. Jun. 1999; 14(6):1143-51.
Salles et al. “Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the Gela-Goelams FL2000 study” Blood 2008; 112:4824-4831.
Santini et al. “Type I Interferon as a Powerful Adjuvant for Monocyte-derived Dendritic Cell Development and Activity in Vivo and in Hu-PBL-SCID Mice” J. Exp. Med. 191(10):1777-1788 (2000).
Scott et al. “Type II Regulatory Subunit Dimerization Determines the Subcellular Localization of the cAMP-dependent Protein Kinase”, J. Biol. Chem. 265:21561-66 (1990).
Scott et al. “Cyclic nucleotide-dependent protein kinases” Pharmacol. Ther. 1991;50(1):123-45.
Sharkey et al. “Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody”, Cancer Res. 68:5282-90, 2008.
Sharkey et al. “Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model”, Radiology 246:497-507, 2008.
Sidky and Borden “Inhibition of Angiogenesis by Interferons: Effects on Tumor- and Lymphocyte-induced Vascular Responses” Cancer Res. 47:5155-5161, Oct. 1, 1987.
Stein et al. “Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma” Clin. Cancer Res. vol. 10, 2868-2878, Apr. 15, 2004.
Stein et al. “Characterization of a humanized IgG4 anti—HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab” Blood 2006;108:2736-2744.
Stokka et al. “Characterization of A-kinase-anchoring disruption using a solution-based assay” Biochem. J. (2006) 400, 493-499.
Takaoka et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence Nature Jul. 31, 2003;424(6948):516-23.
Taylor, S. “cAMP-dependent Protein Kinase” J. Biol. Chem. 1989;264(15):8443-8446.
Walsh et al. “An Adenosine 3′, 5′-Monophosphate-dependant Protein Kinase from Rabbit Skeletal Muscle” J. Biol. Chem. 243(13)3763-3774 (1968).
Weck et al. “Comparison of the Antiviral Activities of Various Cloned Human Int
Chang Chien-Hsing
Goldenberg David M.
McBride William J.
Rossi Edmund A.
Huynh Phuong
IBC Pharmaceuticals, Inc.
Nakashima Richard A.
LandOfFree
PEGylation by the dock and lock (DNL) technique does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PEGylation by the dock and lock (DNL) technique, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PEGylation by the dock and lock (DNL) technique will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201428